Amgen (AMGN) 10-K Summary — Year Ended Dec 31, 2024
Amgen discovers, develops, manufactures, and delivers innovative medicines for serious diseases. The company reported higher revenue and operating income for the year, with operating cash flow exceeding net income.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
Amgen discovers, develops, manufactures, and delivers innovative medicines for serious diseases. The company reported higher revenue and operating income for the year, with operating cash flow exceeding net income.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$33.4B
Revenue reported for the fiscal year.
Operating income
$7.3B
Income from operations reported for the year.
Net income
$4.1B
Net income reported for the year.
Operating cash flow
$11.5B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $26B | n/a |
| Dec 31, 2022 | $26.3B | +1.3% |
| Dec 31, 2023 | $28.2B | +7.1% |
| Dec 31, 2024 | $33.4B | +18.6% |
Business overview
Amgen is a leading independent biotechnology company that focuses on areas of high unmet medical need. Its principal products include Prolia, ENBREL, XGEVA, Repatha, Otezla, and several others. The company also markets additional products such as AMJEVITA, MVASI, and Neulasta.
Financial performance
Revenue increased compared to the prior year, and operating income also rose. Net income was lower than operating cash flow, indicating strong cash generation from operations.
Material risks
The filing includes risk factors related to the company's business, operations, and regulatory environment. These risks are detailed in Item 1A of the report and cover areas such as product development, competition, and government regulation.
Liquidity and capital
The company discusses liquidity and capital resources, including trends, planned dividends, stock repurchases, and collaborations. No specific capital allocation decisions beyond these themes are detailed in the supplied context.
What to watch
Monitor updates on the company's pipeline of potential first-in-class medicines at all stages of development.